Author/Authors :
Frank Brady، نويسنده , , Sajinder K. Luthra، نويسنده , , Gavin Brown، نويسنده , , Safiye Osman، نويسنده , , Robert J. A. Harte، نويسنده , , William A. Denny، نويسنده , , Bruce C. Baguley، نويسنده , , Terry Jones، نويسنده , , Patricia M. Price، نويسنده ,
Abstract :
The potential anti-cancer agent n-[2-(dimethylamino)ethyl]acridine-4-carboxamide, DACA has been labelled with carbon-11. N-[2-11C-methyl]DACA was produced in 73% radiochemical yield from [11C]iodomethane in 40 min from EOB. The average radiochemical yield was 3.2 GBq with specific radioactivity of 41.5 GBq μmol−1 at EOS, corresponding to 24 μg of stable DACA. The position of labelling was confirmed by co-labelling with [11/13C]iodomethane.
PET studies in patients have been performed prior to Phase I trial of DACA and during Phase I trial of DACA. Analysis of serial plasma samples showed that the metabolism of N-[2-11C-methyl]DACA is rapid and extensive in patient plasma.
